![Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/4/e002114/F1.large.jpg)
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
![Study of NSCLC, melanoma outcomes points to surrogacy between real-world endpoints and clinical trial endpoints - The Cancer Letter Study of NSCLC, melanoma outcomes points to surrogacy between real-world endpoints and clinical trial endpoints - The Cancer Letter](https://cdn.cancerletter.com/media/2020/09/story2-2-2.jpg)
Study of NSCLC, melanoma outcomes points to surrogacy between real-world endpoints and clinical trial endpoints - The Cancer Letter
![Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis | The BMJ Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis | The BMJ](https://www.bmj.com/content/bmj/378/bmj-2022-070346/F2.large.jpg)
Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis | The BMJ
![JCM | Free Full-Text | Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy JCM | Free Full-Text | Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy](https://pub.mdpi-res.com/jcm/jcm-11-01500/article_deploy/html/images/jcm-11-01500-g001.png?1646820587)
JCM | Free Full-Text | Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy
![Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive](https://archive.cancerworld.net/wp-content/uploads/2015/10/Correlation-by-itself-does-not-imply-surrogacy.jpg)
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
![Are there differences between progression-free survival, relapse-free survival, and recurrence-free survival? | ResearchGate Are there differences between progression-free survival, relapse-free survival, and recurrence-free survival? | ResearchGate](https://www.researchgate.net/profile/Eman-Toraih/post/Are-there-differences-between-progression-free-survival-relapse-free-survival-and-recurrence-free-survival/attachment/61d65bfcd248c650edbe130e/AS%3A1109086368219137%401641438204958/download/types+of+survival+times.png)
Are there differences between progression-free survival, relapse-free survival, and recurrence-free survival? | ResearchGate
![Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley](https://acsjournals.onlinelibrary.wiley.com/cms/asset/7ec0391a-b577-4b44-aac8-535a76de8de5/cncr30934-fig-0001-m.jpg)
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
![Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-020-0805-y/MediaObjects/41416_2020_805_Fig1_HTML.png)
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
![Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41571-023-00823-5/MediaObjects/41571_2023_823_Fig2_HTML.png)
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology
![Cancers | Free Full-Text | Systematic Analysis of Accuracy in Predicting Complete Oncological Resection in Pancreatic Cancer Patients—Proposal of a New Simplified Borderline Resectability Definition Cancers | Free Full-Text | Systematic Analysis of Accuracy in Predicting Complete Oncological Resection in Pancreatic Cancer Patients—Proposal of a New Simplified Borderline Resectability Definition](https://www.mdpi.com/cancers/cancers-12-00882/article_deploy/html/images/cancers-12-00882-g002.png)
Cancers | Free Full-Text | Systematic Analysis of Accuracy in Predicting Complete Oncological Resection in Pancreatic Cancer Patients—Proposal of a New Simplified Borderline Resectability Definition
![Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials - Matulonis - 2015 - Cancer - Wiley Online Library Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials - Matulonis - 2015 - Cancer - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/c787f601-c0f2-4f8b-b5f9-710b7ccfcbff/cncr29082-fig-0002-m.jpg)
Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials - Matulonis - 2015 - Cancer - Wiley Online Library
![Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? - NCBI Bookshelf Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-methrespfs-lrg.png)
Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? - NCBI Bookshelf
![Definition of progression free survival and overall survival for the... | Download Scientific Diagram Definition of progression free survival and overall survival for the... | Download Scientific Diagram](https://www.researchgate.net/publication/265644752/figure/fig1/AS:269802786783234@1441337405030/Definition-of-progression-free-survival-and-overall-survival-for-the-Gold-standard-and.png)